通心络胶囊联合门冬氨酸钾镁治疗室性心律失常患者的效果

Effects of Tongxinluo capsules combined with Potassium magnesium aspartate in treatment of patients with ventricular arrhythmia

目的:观察通心络胶囊联合门冬氨酸钾镁治疗室性心律失常患者的效果。方法:回顾性分析2021年5月至2022年3月该院收治的88例室性心律失常患者的临床资料,按照治疗方法不同将其分为对照组和观察组各44例。两组均予以基础治疗,在此基础上,对照组予以门冬氨酸钾镁治疗,观察组在对照组基础上联合通心络胶囊治疗,两组均治疗4周。比较两组临床疗效,治疗前后心率变异性指标[相邻两个窦性RR间期差值>50 ms的心搏数占全部心搏数的百分比(PNN50)、全部相邻窦性RR间期差值的均方根(RMSSD)、全部窦性RR间期标准差(SDNN)、每5 min窦性RR间期均值标准差(SDANN)]水平、炎性指标[白细胞介素-6(IL-6)、核因子-κB(NF-κB)、基质金属蛋白酶-9(MMP-9)、可溶性CD40配体(sCD40L)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.45%(42/44),高于对照组的81.82%(36/44),差异有统计学意义(P<0.05);治疗后,观察组PNN50、RMSSD、SDNN、SDANN水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组IL-6、NF-κB、MMP-9、sCD40L水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:通心络胶囊联合门冬氨酸钾镁治疗室性心律失常患者可提高治疗总有效率和心率变异性指标水平,降低炎性指标水平,效果优于单纯门冬氨酸钾镁治疗。

Objective:To observe effects of Tongxinluo capsules combined with Potassium magnesium aspartate in treatment of patients with ventricular arrhythmia.Methods:The clinical data of 88 patients with ventricular arrhythmia admitted to this hospital from May 2021 to March 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,44 cases in each group.Both groups were given basic treatment.On this basis,the control group was treated with Potassium magnesium aspartate,while the observation group was treated with Tongxinluo capsules on the basis of that of the control group.Both groups were treated for 4 weeks.The clinical efficacy,the levels of heart rate variability indexes[proportion of adjacent NN intervals differing by>50 ms(PNN50),root mean square successive differences between successive RR intervals(RMSSD),standard deviation of NN intervals(SDNN),standard deviation of mean value of sinus RR intervals every 5 min(SDANN)]and inflammatory indexes[interleukin-6(IL-6),nuclear factor-kappa B(NF-κB),matrix metalloproteinase-9(MMP-9),soluble CD40 ligand(sCD40L)],and the incidence of adverse reactions was compared between two groups before and after the treatment.Results:The total effective rate of the observation group was 95.45%(42/44),which was higher than 81.82%(36/44)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PNN50,RMSSD,SDNN and SDANN in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-6,NF-κB,MMP-9 and sCD40L in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tongxinluo capsules combined with Potassium magnesium aspartate in the treatment of the patients with ventricular arrhythmia can improve the total effective rate and the levels of heart rate variability indexes,and reduce the levels of inflammatory indexes.Moreover,it is superior to single Potassium magnesium aspartate treatment.